✦ LIBER ✦

Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

✍ Scribed by Pauline Wimberger; Nils Lehmann; Rainer Kimmig; Alexander Burges; Werner Meier; Berit Hoppenau; Andreas du Bois

Book ID: 113960222
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 226 KB
Volume: 100
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2005.08.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors for complete debulkin

Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

✍ Pauline Wimberger; Nils Lehmann; Rainer Kimmig; Alexander Burges; Werner Meier; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 238 KB

Cisplatin/paclitaxel vs. carboplatin/pac

Cisplatin/paclitaxel vs. carboplatin/paclitaxel in 798 patients with ovarian cancer FIGO IIB-IV — Randomized phase III study the AGO (Arbeitsgemeinschaft Gynaekologische Onkologie) study group (OVAR-3 trial)

✍ Costa, S.D.; du Bois, A.; Lueck, H.J.; Meier, W.; Moebus, V.; Bauknecht, T.; Ric 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 197 KB

Topotecan versus treosulfan, an alkylati

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

✍ Werner Meier; Andreas du Bois; Alexander Reuss; Walther Kuhn; Sigrid Olbricht; M 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 545 KB

Docetaxel and carboplatin as first-line

Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group

✍ J Pfisterer; A du Bois; U Wagner; J Quaas; J.U Blohmer; D Wallwiener; F Hilpert 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 123 KB

Role of surgical outcome as prognostic f

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials : By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)

✍ Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 359 KB 👁 1 views

Addition of vandetanib to pegylated lipo

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)

✍ Harter, Philipp; Sehouli, Jalid; Kimmig, Rainer; Rau, JÃ¶rn; Hilpert, Felix; Kur 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 162 KB